4beta-hydroxycholesterol in Cirrhosis

Suspended

• Conditions: Cirrhosis, Liver

• Registration Number: NCT04199910
• Lead Sponsor: University of Oulu

Brief Summary

The aim is to evaluate the levels of oxysterols and especially 4beta-hydroxycholesterol in patients with liver cirrhosis. Three cirrhosis cohorts are recruited: patients treated with spironolactone, patients treated with rifaximin, patients without spironolactone or rifaximin. Also three other control cohorts are recruited: patients with pneumonia, patients with Crohn's disease, patients with ulcerative colitis. The effect of the cirrhosis and its medications spironolactone and rifaximin are compared to control groups.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-12-01
• Study First Submitted: 2019-12-11
• Study First Submitted QC: 2019-12-13
• Study First Posted: 2019-12-16
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-07
• Last Update Posted: 2024-05-08
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: SUSPENDED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Patients with cirrhosis, pneumonia, Crohn's disease or colitis ulcerosa
• Treated in the ward 42 of the Oulu University Hospital

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood 4beta-hydroxycholesterol concentration	At the time point of the blood collection - cross-sectional. One day.	Blood 4beta-hydroxycholesterol concentration

Trial Locations

Locations (1)

Oulu University Hospital; 🇫🇮 Oulu, Finland